
FDA Provides Answers to Biologics License Questions
A guidance document answers questions regarding the transition of biologics applications from under the FD&C Act to the PHS Act.
FDA issued a
Specifically, the document describes the types of products affected by the transition and provides information about application and license numbers; agency office review procedures; chemistry, manufacturing, and control changes; and other requirements. The agency also describes the labeling compliance policy for biologics license applications.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.